CHICAGO, August 1, 2022 /PRNewswire/ — COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in the treatment of autoimmune diseases, today announced the publication of data in collaboration with the Miller Laboratory in Northwestern University, demonstrating durable tolerance using its novel platform technology in the non-obese diabetic (NON-Obese Diabetic, NOD) type 1 diabetes (T1D) model, the gold standard model of autoimmunity. These findings for the COUR T1D program provide proof of principle for a potential paradigm shift in T1D treatment to move patients away from lifelong patient-directed management of burdensome lifestyle adjustments and daily insulin injections by halting the progression of the disease. The effects of such treatment may delay the need for insulin. The research manuscript entitled “Tolerogenic immunomodifying nanoparticles encapsulating multiple recombinant pancreatic β cell proteins prevent the onset and progression of type 1 diabetes in non-obese diabetic mice” was selected by the peer-reviewed the journal of immunology as a top read for their August 1St2022 issue and is available online at https://www.jimmunol.org/content/early/2022/06/19/jimmunol.2200208.
“This is the first time a therapy has maintained normal glycemic levels in the NOD model, one of the most challenging models for T1D and autoimmunity,” said Stephen Miller, PhD, Professor of Microbiology-Immunology. “In the NOD model, treatment with the COUR NanoParticle Platform, encapsulating mouse disease-related antigens, prevented the destruction of beta cells in the pancreas, halting disease progression. The mechanism of action of CNP is the induction of regulatory T cells, which inhibit the infiltration of inflammatory autoreactive T cells into the pancreas, where they would otherwise destroy the insulin-producing beta cells. Encapsulation of multiple disease epitopes within CNPs is necessary to provide sufficient coverage to arrest the progression of complex disease that is driven by multiple antigens.
“The results of this preclinical study are very exciting and the COUR team is passionate about bringing the COUR NanoParticle Platform encapsulating human disease-related antigens (CNP-103) into the clinic to provide a potentially life-changing therapy for patients suffering from 1 diabetes. At the rapid pace of innovation, this is the first time in a decade to demonstrate a profound milestone in the field of immunology,” said John J. Thenfounder and CEO of COUR Pharmaceuticals.
CNP-103 is a first-in-class therapeutic designed to reprogram the immune system to address the immunological root cause of disease in type 1 diabetes. CNP-103 is a promising approach that uses COUR’s proprietary nanoparticles that encapsulate multiple human diabetogenic proteins to induce Ag- specific tolerance, rebalancing the immune system through antigen-specific immune reprogramming to stop immune-mediated destruction of pancreatic islet cells.
About COUR Pharmaceuticals
COUR Pharmaceuticals develops first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance to immune-mediated diseases. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches that only minimize symptoms by toxically suppressing the immune system. COUR’s lead product for celiac disease, in partnership with Takeda Pharmaceutical Company, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the potential of the COUR NanoParticle platform to address a wide range of immune and inflammatory conditions. The core technology was acquired from Northwestern University and is based on more than 30 years of immune tolerance research. For more information, please visit www.courpharma.com.
SOURCE Cour Pharmaceutical Development Company Inc.